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Summary. Advances in therapy have improved life
expectancy and quality of life of patients with
haemophilia A. Due to the chronic and complex
management of this disease, particularly, the develop-
ment of inhibitors, little is known about their health
resource utilization in the real-life setting over time.
The aim was to assess the distribution and trend of
healthcare resource utilization among US haemophilia
A patients with and without inhibitors. The Market-
Scan Database, was queried to identify individuals
with ‡1 year continuous enrolment, two medical
diagnoses of haemophilia A and claims for factor VIII
or bypassing agent (to infer inhibitor status) during
2001–2007. Haemophilia-related cost was estimated
from inpatient, outpatient and pharmacy claims.
Annual cost differences were assessed by age and over
a 4-year period for those with continuous enrolment.
Among 51 million covered lives, 1044 haemophilia
patients were identified, of whom 981 (94%; mean
age = 21.2 years) did not have an inhibitor. The
median haemophilia-related cost for these patients
was $63,935 per patient per year. When normalized
by weight, annual cost was stable (no statistically
significant differences) among 312 non-inhibitor
patients (mean age = 21.8 years) with 4-year continu-
ous data. While there was a wide distribution of
haemophilia-related cost among the 63 individuals
with an inhibitor (mean age = 15.4 years), only 0.6%
of the total haemophilia patients had costs exceeding
$1 million per patient per year. This study indicated
that most haemophilia A patients were inhibitor-free
with relatively stable annual costs over time. There
was a wide distribution of haemophilia-related cost for
inhibitor patients, while the proportion of patients
who incurred extreme high cost was low.
Keywords: cost, economics, haemophilia, inhibitors, sur-
gery
Introduction
Haemophilia A is a rare, genetic bleeding disorder
resulting from the deficiency of factor VIII (FVIII)
activity. Patients with this condition may have easy
bruising and excessive bleeding. Complications from
bleeding include pain, swelling, limited range of motion
of joints and reduced quality of life (QoL). Bleeding that is
uncontrolled or into a vital structure may result in death.
Treatment of haemophilia A involves replacing FVIII
activity, typically by injection of either plasma-derived
or recombinant FVIII. Due to the chronic and complex
nature of the disease, clinical management of haemo-
philia A patients is heavily impacted by disease severity,
weight, treatment regimen, complications and other
factors [1–4]. The treatment pattern for haemophilia
has evolved significantly over time, in particular, with
paediatric patients. In the US in 1995, the prevailing
practice was to utilize FVIII treatment in response to
bleeding episodes (on-demand treatment) and only 33%
of children with haemophilia received regular adminis-
tration of FVIII (prophylaxis) [5]. In the last decade,
prophylaxis treatment has increased, especially in young
patients [6–8]. This increase in prophylaxis use is
attributable to recent evidence that it reduces bleeding
episodes and joint disease [9,10]. This and advances in
therapy agents have raised the life expectancy of
haemophilia A patients to near normal [11] and
significantly improved their QoL [12].
From a clinical perspective, haemophilia A has been
transformed from a fatal disease to a well-managed,
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chronic disease for patients who have not developed
complications. However, the onset of complications,
particularly development of inhibitors, may add signif-
icant complexity to disease management [13]. Cur-
rently, prevalence of inhibitors among haemophilia A
patients is 5–7% [14] and the cumulative incidence is
20–30% [14–16]. The presence of inhibitors greatly
impacts the health and QoL of haemophilia A patients,
due to the difficulty to control bleeding and joint disease
[17,18]. Treatment of inhibitor patients may involve
immune tolerance induction (ITI) to eradicate inhibitors
and clotting agents, such as activated recombinant FVII
(rFVIIa) or an activated prothrombin complex concen-
trate (aPCC) to bypass inhibitors in an attempt to
control bleeding episodes [19]. Clinical management of
haemophilia patients with inhibitor development is
individualized to a large extent due to the many ITI
protocols available and different patient responses to
ITI, aPPC and rFVIIa [20–22].
Given improvement in life expectancy, the potential
for complications and the complexity of individualized
treatment of inhibitor patients, it is important to
understand the health resource utilization among hae-
mophilia A patients. This study assesses the trend and
distribution of healthcare resource utilization and
treatment costs of haemophilia A patients by looking
at real-world data in a large US health insurance claims
database. It also sheds light on the distribution of
healthcare resource utilization associated with inhibitor
management.
Methods
Data source
The MedStat MarketScan Database, a large US
healthcare claims database including data from
employer-based commercial health plans, Medicare
Supplemental and Medicaid sources was analysed. The
dataset includes medical claims (i.e. inpatient/
outpatient), outpatient pharmacy claims and annual
enrolment information from 2001 to 2007.
Sample selection
Inclusion criteria were male individuals with at least two
diagnoses for haemophilia A (ICD-9-CM 286.0-congen-
ital FVIII disorder) recorded at least 30 days apart. The
first haemophilia A diagnosis identified in the database
became the index date. Furthermore, they were required
to have at least 1 year of continuous eligibility after the
index date and at least one outpatient pharmaceutical
claim for a FVIII product or bypassing agent. Individuals
receiving at least one bypassing agent (i.e. aPCC or
rFVIIa) were defined as inhibitor patients and the others
as non-inhibitor patients.
Statistical analysis
The variables analysed were age at index date and
haemophilia-related cost, including inpatient, out-
patient and drug cost related to haemophilia treatment.
Due to potential impact of growth-related weight gain
on the rising annualized cost per patient in the paedi-
atric population, annual haemophilia-related cost per
patient was normalized by weight (per kg). Patient
weight was not available and therefore estimated using
the proxy data from CDC growth charts [23]. Due to
the skewed distribution of cost data, non-parametric
statistics were used to assess cost differences between
patient subgroups and over time. Mixed model regres-
sion was used to assess the effect of time on annualized
cost per kg among a group of 312 patients who had
4-year continuous enrolment data. Dollars were
adjusted to 2007 amount. Cost was adjusted to 2007
dollars using the Consumer Price Index – Medical Care
Services Factor published by the United States Bureau of
Labor Statistics [24].
Results
Patient characteristics
Figure 1 is a flow chart of sample selection. Among the
51 million covered lives assessed in the database, 1044
individuals (mean age = 20.9 years) met the sample
selection criteria for the study and were defined as
haemophilia A patients. Of these patients, 94% (981/
1044) were identified as non-inhibitor patients during
the eligible study period. Table 1 summarizes study
population by age groups and inhibitor status. The ages
of the non-inhibitor patients were relatively evenly
distributed. It was expected that the number of patients
Number of unique patients in MarketScan® 
Database (2001–2007) 
N = 51 million 
Male with ≥2 ICD-9 codes of Hemophilia A recorded at  
least 30 days apart  
N = 2401 
≥ 12 months of continuous enrollment after index date (1st
hemophilia A diagnosis in the database)
N = 1778 
≥1 claim of FVIII or bypassing agent 
N = 1044 
N = 981 N = 63 
≥1 claim of bypassing agent ≥1 claim of FVIII only  
Fig. 1. Summary of the sample flow.
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in the ‡21 age group would be larger due to the wide
age range in this group. Also as expected, the highest
percentage (35%) of inhibitor patients was in the 0–
5 year age group. The overall prevalence of inhibitors in
the study population was 6% (63 of 1044).
Cost of non-inhibitor patients
Haemophilia-related expenses were first examined for
patients who did not have an inhibitor as defined above.
Median annual haemophilia-related cost was $63 935
(Fig. 2). The majority of the cost came from haemo-
philia drug spending (median = $47 626). The medians
of the inpatient and outpatient cost were 0 and $867,
respectively. When stratified by age groups, the median
annual haemophilia-related cost increased significantly
(P < 0.05) for patients from birth to about 15 years,
remained stable thereafter until 20 years and dropped
significantly after patients reached 21 years of age
(P < 0.05). When normalized by weight (Fig. 3), there
was no statistically significant difference in annualized
cost per kg among patient age groups £20 years.
However, those ‡21 years of age had a median annual
cost per kg of $595 which was significantly lower
compared with any age group less than 21 years
(P < 0.001).
To determine the cost trend for managing non-
inhibitor haemophilia patients over time, longitudinal
data were analysed for a cohort of 312 non-inhibitor
patients (mean age = 21.8 years, median age = 14
years), who had over 4-year continuous enrolment in
the database. As more than half of the 312 patients were
paediatric patients under the age of 18, the annual cost
was normalized by weight to control the possible weight
gain during the 4-year period. Figure 4 presents the
median annualized cost per kg over the 4-year interval
for these patients. There was no significant difference in
year-to-year change over the 4 years based on Wilcoxon
signed rank test. Mixed regression analysis treating time
as fixed effects was employed to further examine the
effect of time on cost. The effect of time was not
significant, confirming the stability of cost per kg over
time.
Cost of inhibitor patients
A small percentage of haemophilia A patients (6%)
utilized a bypassing agent in this study. The medians for
the inpatient, outpatient and drug costs were $7004,
$3430 and $191 301, respectively. There was a wide
distribution of annual haemophilia-related cost in these
patients, ranging from $16 013 for patients in the 10th
percentile to $1 031 314 for those in the 90th percen-
tile, with a median cost of $271 357 (Fig. 5). Impor-
Table 1. Patient age distribution by inhibitor status.
Age at
index
date
Total number
by age
group (%*)
Number of
non-inhibitor patients
by age group (%)
Number of inhibitor
patients by age
group (%)
0–5 199 (19) 177 (18) 22 (35)
6–10 179 (17) 167 (17) 12 (19)
11–15 163 (16) 153 (16) 10 (16)
16–20 130 (12) 126 (13) 4 (6)
‡21 373 (36) 358 (36) 15 (24)
Total 1044 (100) 981 (100) 63 (100)
Mean 20.9 ± 18.3 21.2 ± 18.3 15.4 ± 16.7
Median 15 (0–88) 15 (0–88) 9 (0–44)
*Percentage is calculated as the number of patients in the age group divided
by the total number of patients in the category.
$63 935
(N = 981)
$21 606
(N = 177) 
$72 547
(N = 167)
$124 019
(N = 153)
$112 581
(N = 126)
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Fig. 2. Median annual haemophilia-related cost
by age group for non-inhibitor patients
(N = 981). *P < 0.05 for cost comparison
between adjacent groups (P values were com-
puted using the Wilcoxon rank sum test). NS: not
significant.
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tantly, the proportion of inhibitor patients who had an
annual cost exceeding $1 million accounted for only
0.6% of the total haemophilia A study population (6 of
1044 patients).
Closer examination of the subset of patients with
inhibitors by age group and by weight revealed that the
highest cost/kg was found among the 0–5 years age
group (Fig. 6). The youngest population had a statisti-
cally significant higher annual cost/kg over the 6–10 and
‡21 age groups (P < 0.05). The small sample size in the
11–15 and 16–20 age groups may account for the lack
of statistically significant difference compared to the
0–5 population. When comparing all age groups older
than 5 years, cost per kg was not significantly different.
To determine other possible contributing factors
towards the cost of haemophilia A patients with inhibitor
development, surgery status and type of bypassing
agents were analysed. The years in which inhibitor
patients underwent at least one surgical procedure
resulted in significantly higher cost (median = $286 609)
compared with years without surgery (median =
$68 379) (P < 0.05) (Fig. 7). In a comparison of cost
for inhibitor patients treated with either aPCC or rFVIIa
(not both), the median annual haemophilia-related cost
was $160 019 for patients utilizing aPCC (n = 16) and
$258 824 (n = 29) for patients treated with rFVIIa.
However, no statistically significant difference was
detected, possibly due to the small sample sizes.
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Fig. 3. Median annual haemophilia-related cost
per kg by age group for non-inhibitor patients
(N = 981). **P < 0.001 (P values were computed
using the Wilcoxon rank sum test). The significant
difference of annual cost per kg for the ‡21 age
group was in comparison with all other age
groups. There was no significant difference in
annual cost per kg when comparing every other
two groups.
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Fig. 4. Median haemophilia-related cost per
kg over 4 years for non-inhibitor patients
(N = 312). No differences were statistically
significant.
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Discussion
Utilizing a large US healthcare database, this study
showed that the great majority (94%) of haemophilia A
study patients did not develop inhibitors during the
observation period and their total haemophilia-related
treatment cost per patient per year was similar to what
has been reported by other studies [1,2]. It also confirmed
the known prevalence rate (6%) of inhibitors, within the
range of what has been reported in the literature [14,25].
This study further assessed the impact of age and
weight on cost of haemophilia treatment. When nor-
malized by weight, there was no statistical difference in
total haemophilia-related cost among non-adult age
groups (£20 years of age). However, there was a
significant decrease in cost for the ‡21 adult group vs.
other age groups. The weight normalized cost differ-
ences between adults and children was consistent with
the treatment pattern that a greater percentage of young
patients are on a continuous prophylaxis regimen
compared to adults [5,9]. Even when prophylaxis is
prescribed, older patients were reported less likely to be
adherent than younger patients [26].
In managing chronic diseases, it is always important
to understand the total cost pattern over time. This is
the first study that retrospectively followed a cohort of
non-inhibitor haemophilia patients to analyse haemo-
philia-related costs over a 4-year time period. This
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Fig. 5. Distribution of annual haemophilia-
related cost among inhibitor patients (N = 63).
The proportion of inhibitor patients, who had a
cost exceeding $1 million per patient per year,
accounted for only 0.6% of the total haemophilia
A patients.
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Fig. 6. Median annual haemophilia-related cost
per kg by age group for inhibitor patients
(N = 63). *P < 0.01 (P values were computed
using the Wilcoxon rank sum test). Significant
differences (P < 0.01) seen only between age
groups 0–5 and 6–10, as well as between 0–5 and
‡21. All other age groups did not have significant
differences in comparison with each other,
possibly due to small sample size.
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approach allowed assessment of the cost trend over time
in the real-world setting. Although the median weight
normalized cost (cost per kg) showed a slight declining
trend, there was no statistically significant year-to-year
variation over the 4-year period. This result was further
confirmed by regression model showing that time did
not have a significant effect on haemophilia-related cost
per kg. These findings suggested that haemophilia
patients were well-maintained and in relatively consis-
tent clinical condition during the study period, which
resulted in stability of total treatment costs over time.
A small proportion (0.6%) of patients had high cost
of care (>$1M) due to inhibitor status. Interestingly,
other analyses have shown that mean cost of inhibitor
patients is inflated by a small number of patients with
extreme outlier costs and after adjusting for these
outliers, the cost of outpatient clotting factor replace-
ment products was not significantly greater among
inhibitor patients compared to non-inhibitor patients
[27–29]. The management of patients with inhibitors to
FVIII is complicated by less predictable responses to
therapy with bypassing agents compared to replacement
therapy in patients without inhibitors [21,22], which
likely involves patient-specific factors and factors
related to therapy agents, including the mechanisms of
action and pharmacokinetic profiles. Therefore, inhib-
itor management is complex, making the widespread
variation in costs understandable as care must be
individualized not only for each patient, but also for
specific haemorrhagic situations [4,30–32]. Co-determi-
nants of cost in this study included age, weight, surgery
and possibly which bypassing agent an inhibitor patient
used. This study showed that patients £5 years cost
significantly more per kg than any other age group,
possibly indicating that treatment of inhibitors for some
of these patients involved ITI to eradicate inhibitors in
combination with bypassing clotting agents. It may also
reflect the lack of and/or differential responsiveness
inherent in managing this rare population of haemo-
philia patients. The wide variation in overall haemo-
philia-related cost among patients with inhibitors
demonstrates that optimized and individualized care is
necessary among this small patient population.
The limitations of this study include the absence of
patient-specific data, including haemophilia severity.
However, patients with mild disease who did not use a
FVIII product to treat bleeding would not be included in
the analysis. Furthermore, there was no diagnosis code
available for the identification of inhibitor patients and
therefore this patient subgroup was operationally defined
by utilization of bypassing agents. Presumably, there
could have been inhibitor patients that were not identi-
fied, including those receiving FVIII for ITI and not
having breakthrough bleeding requiring administration
of a bypassing agent. In addition, prophylaxis use could
be a confounding factor for cost. Such information was
not available in the data. Therefore, the impact on cost
from prophylactic treatment remained unknown. Finally,
the actual weight of patients was not available and
therefore the CDC average weight chart was used for any
normalization to weight.
Conclusion
This study demonstrates that most haemophilia A
patients were inhibitor-free (94%) and haemophilia-
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Fig. 7. Median haemophilia-related cost for
inhibitor patients by surgery status. *P < 0.05 (P
values were computed using the Wilcoxon rank
sum test). Analysis of annual cost between surgery
and non-surgery patients is based on person-year
data. Each year of data per patient was catego-
rized as either a surgery or non-surgery year.
N = 51 years (30 patients) for non-surgery;
N = 136 years (57 patients) for surgery.
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related cost for most non-inhibitor patients was rela-
tively stable over time with no significant year-to-year
variation detected. In contrast, there was a wide
distribution of haemophilia-related cost for inhibitor
patients, while the proportion of patients who incurred
extremely high costs was relatively low (0.6%). This
study provides a real-world snapshot of haemophilia-
related cost and advances the understanding of treat-
ment patterns and the cost for treatment of haemophilia
A patients with and without inhibitors to FVIII.
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